Total revenues for Jazz Pharmaceuticals plc in 2024 grew 6% year-over-year, as the Dublin, Ireland-based company generated more than $1.4 billion in cash from operations, including sales of the sodium oxybate therapies Xywav and Xyrem. The sodium oxybate product mix looks different from the same periods in 2023 however, reflecting more users of low-sodium oxybate, as well as sales of generics of high-sodium oxybate.
Sleep Medicine Commercial Updates
Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution:
- Xywav net product sales increased 16% to $1,473.2 million in 2024 and increased 19% to $401.0 million in 4Q24 compared to the same periods in 2023.
- Meaningful Xywav net patient adds in 4Q24 (approximately 525 patients) with approximately 14,150 active Xywav patients exiting 4Q24, comprised of:
- Approximately 10,250 narcolepsy patients.
- Approximately 3,900 idiopathic hypersomnia (IH) patients, with 350 net patient adds.
- Xywav is a low-sodium oxybate branded treatment for narcolepsy and the only US Food and Drug Administration-approved therapy to treat IH.
Xyrem (sodium oxybate) oral solution and high-sodium oxybate authorized generic royalties:
- Xyrem net product sales decreased 59% to $233.8 million in 2024 and decreased 54% to $49.3 million in 4Q24 compared to the same periods in 2023.
- Royalties from high-sodium oxybate authorized generics increased by $141.7 million to $217.6 million in 2024 and increased $15.9 million to $55.3 million in 4Q24, compared to the same periods in 2023.
Total neuroscience revenue, including high-sodium oxybate authorized generics royalty revenue, was $2,915.9 million in 2024, an increase of 5% compared to $2,783.8 million in 2023 and $785.8 million in 4Q24, an increase of 8% compared to $728.9 million in 4Q23. The increase in 2024 and 4Q24 was due to higher Xywav and Epidiolex/Epidyolex (for seizures) net product sales together with increased high-sodium oxybate AG royalty revenue, partially offset by decreased Xyrem net product sales.
“2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total revenues of over $4 billion. Our diversified portfolio spanning sleep, epilepsy and oncology, with each annualizing at over $1 billion, continued to drive growth,” says Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, in a release.
